Beam Therapeutics presents BEAM-302 data at conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St futures fall as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
May 18, 2026 4:00 PM EDTCAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation... More



